Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
477.9 (USD) • At close September 19, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Vertex Pharmaceuticals Incorporated |
Symbool | VRTX |
Munteenheid | USD |
Prijs | 477.9 |
Beurswaarde | 123,346,945,322 |
Dividendpercentage | 0% |
52-weken bereik | 341.85 - 510.64 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Reshma Kewalramani FASN, M.D. |
Website | https://www.vrtx.com |
An error occurred while fetching data.
Over Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)